Comparing two immune therapy infusions for nerve damage
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether a new immune therapy called XEMBIFY works as well as a standard treatment (Gamunex-C) for CIDP, a condition where the immune system damages nerves and causes weakness. Both are given as infusions under the skin every three weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CIDP (chronic inflammatory demyelinating polyradiculoneuropathy) or a CIDP variant, confirmed by neurologists
- You weigh 90 kg (about 198 lbs) or less
- You are currently stable on immune therapy infusions and haven't had a disease flare-up in the last 12 weeks
- You need a dose between 20–90 grams of immune therapy every three weeks
- You have no other serious illnesses (like heart failure, advanced kidney disease, active cancer, or bleeding disorders) that would make the study unsafe
- You have not had blood clots, strokes, or heart attacks in your medical history
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
This study looks at how well current treatments work for people with CIDP (a nerve condition causing weakness). It tracks symptoms and daily function over time to help doctors understand which treatments may work best.
This study tests if TAK-881 is as safe and effective as HYQVIA for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). You may join if you have been stable on immune globulin therapy and have certain disability levels.
This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.
This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
Hear when a new CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.